Orchard Therapeutics Limited / GlaxoSmithKline plc

ADA-SCID and Other Rare Inherited Disorders

Disease Overview

ADA-SCID is a fatal inherited primary immunodeficiency caused by adenosine deaminase deficiency that prevents normal T-, B- and NK-cell development; without treatment infants typically die before age two from infection. Metachromatic leukodystrophy (MLD), Wiskott-Aldrich syndrome, transfusion-dependent beta-thalassemia and chronic granulomatous disease are similarly devastating monogenic disorders that can be addressed by autologous ex vivo gene therapy of hematopoietic stem cells. Current alternatives are allogeneic HSCT (donor-dependent, GVHD risk) and, for ADA-SCID specifically, enzyme replacement (Revcovi).

Competitive Landscape

Strimvelis was the first approved autologous ex vivo lentiviral HSC gene therapy globally (EMA 2016), positioning Orchard as the immediate leader in ultra-rare HSC gene therapy upon the GSK transfer. The competing approaches at deal time were allogeneic HSCT (the historical standard for SCID and MLD) and Leadiant's Revcovi enzyme replacement for ADA-SCID — neither of which provided durable single-administration cure. Bluebird bio was the dominant lentiviral peer in the broader HSC gene therapy space, focused on hemoglobinopathies (Zynteglo for TDT) and CALD (Skysona). Sarepta and AAV-based players (Avexis/Novartis Zolgensma) targeted different tissues. The deal mattered because it consolidated multiple late-stage ex vivo HSC programs (OTL-101 for ADA-SCID, OTL-200 for MLD/Libmeldy/Lenmeldy, OTL-300 for TDT, plus WAS and CGD programs) under a dedicated rare-disease vehicle just as GSK was exiting rare disease R&D per Fierce Biotech. Subsequent execution proved mixed: Libmeldy (later Lenmeldy in the US, March 2024 FDA approval per BioPharma Dive) became a commercial reality and Orchard was acquired by Kyowa Kirin in early 2024, but Strimvelis itself had only five commercial sales by the time GSK divested it. The OTL-300 beta-thalassemia and OTL-101 ADA-SCID US filings stalled; Orchard ultimately narrowed focus to severe neurometabolic diseases. [https://www.fiercebiotech.com/biotech/orchard-licenses-gene-therapy-tech-from-gsk]